摘要
观察１０例高血压病患者含服硝苯吡啶前后血压及血管内皮舒张因子（ＮＯ）的改变，结果表明高血压病患者含服硝苯吡啶后收缩压由２２．９６±２．５９ｋＰａ下降至２０．３０±２．６２ｋＰａ，舒张压由１４．１１±１．５６ｋＰａ下降至１２．０７±１．４３ｋＰａ，差异非常显著（Ｐ均＜０．００１）；ＮＯ也由７６０．７０±２２５．９１Ｐｍｏｌ下降至６２１．５０±１９７．４３Ｐｍｏｌ，差异具显著性意义（Ｐ＜０．０５）。这提示高血压病患者含服硝苯吡啶后可降低血压，并使血管内皮衍生舒张因子（ＮＯ）减少。其次，本组结果还表明高血压病患者病程与血管内皮舒张因子呈正相关（ｒ＝０．７０２，Ｐ＜０．０５），从而提示高血压患者内皮舒张因子的调节功能减弱。
The changes of endothelium-derived relaxing factor (Nitric Oxide,NO) and blood pressure were determined in 10 cases of primary hypertention before and after taking nifedipine.The results show the systolic pressure,diastolic pressure and NO were 22.96±2.59kPa,14.11±1.56kPa and 760.70±225.91 nmol separatly before the treatment.After taking nifedipine the level of systolic pressure,diastolic pressure and No were decreased to 20.30±2.62kPa,12.07±1.43kPa and 621.50±197.43nmol separatly and the differences were significant (P<0.05).On the other hand,the time of hypertention was correlated highly to the NO level (r=0.702,P<0.05).Thus,those results suggeSt the regulated decrement of endothelium-derived relaxing factor in primary hypertention.
出处
《河北医学》
CAS
1995年第2期65-67,共3页
Hebei Medicine
关键词
高血压
内皮舒张因子
硝苯吡啶
Hypertention
Endothelium-derived relaxing factor
Nifedipine
